RxDoctor Payments Data

Steven Richards, MD

Family Medicine · Belpre, OHNPI 1275581605

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 52 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Misonix Inc$463
  • KARL Storz Endoscopy-america$270
  • Lifenet Health$187
  • Novartis$135
  • AbbVie$100
  • Amarin Pharma, Inc.$52
  • plus $152 from 6 others

What the payments were for

  • Food & beverage$1,07479%
  • Education$151%
  • Gifts$27020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$193,071
Medicare patients
519
Services billed
2,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$164,204
OzempicSemaglutide84$87,657
JardianceEmpagliflozin78$59,951
MounjaroTirzepatide43$54,018
TrulicityDulaglutide41$51,598
XareltoRivaroxaban39$44,246
FarxigaDapagliflozin Propanediol50$41,797
JanuviaSitagliptin Phosphate28$31,052
MyrbetriqMirabegron32$26,105
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,697
LinzessLinaclotide19$20,504
VraylarCariprazine Hcl14$19,926
EntrestoSacubitril/Valsartan15$16,137
SymbicortBudesonide/Formoterol Fumarate37$15,555
VascepaIcosapent Ethyl24$12,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$164,204176 claims
AbbVieLinzess, Vraylar, Synthroid$100$44,841131 claims
NovartisEntresto$135$16,13715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Belpre

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →